Steven A. Elms, Managing Partner at Aisling Capital, New York, New York, United States — verified investor profile. See sector focus and contact routes.
Steven A. Elms is a Managing Partner at Aisling Capital, a venture firm he joined in 2000, after previously serving as a Principal in life sciences investment banking at Chase H&Q where he facilitated over 60 transactions. Aisling Capital focuses its investment thesis on life science companies in the clinical stage of development, investing in both public and private equity across the sector. While specific check sizes and lead/follow behavior for Elms individually are not publicly detailed, the firm’s preference for clinical-stage life sciences defines its typical engagement. Elms holds significant board roles in the portfolio, serving as Chairman of Elevation Oncology (where he was also Interim CEO) and Adma Biologics, and as a board member for Marker Therapeutics and Zosano Pharma. His portfolio also includes notable companies such as Loxo Oncology, which was acquired by Eli Lilly, and CeNeRx BioPharma. Elms is a recognized figure in the industry, frequently attending the J.P. Morgan Healthcare Conference since the mid-1990s when it was hosted by Hambrecht & Quist. He holds a B.A. in Human Biology from Stanford University and an M.B.A. from Northwes
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in New York.
Investors like Steven A. Elms · Full investor directory · Investor access · Company funding database